This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kelland, L. R. Articles by Harrap, K. R. Search for Related Content PubMed PubMed Citation Articles by Kelland, L. R. Articles by Harrap, K. R.

Mechanism-related Circumvention of Acquired cis-Diamminedichloroplatinum(II) Resistance Using Two Pairs of Human Ovarian Carcinoma Cell Lines by Ammine/Amine Platinum(IV) Dicarboxylates¹

Drug Development Section, The Institute of Cancer Research, Belmont, Sutton, Surrey SM2 5NG [L. R. K., P. M., G. A., S. Y. L., C. F. O., K. R. H.], and Johnson Matthey Technology Centre, Sonning Common, Reading RG4 9NH [B. A. M.], England

Acquired resistance to cisplatin has been generated in vitro in two human ovarian carcinoma cell lines: 41M, established from a previously untreated patient; and CH1, from a patient previously treated with cisplatin and cis-diammine-1,1-cyclobutane dicarboxylatoplatinum(II) (carboplatin). In neither cell line with acquired resistance did intracellular detoxification (via increased glutathione or metallothioneins) appear to be a major determinant of resistance. Resistance in 41McisR (resistance factor of 4.7) appeared to be due predominantly to a reduced platinum accumulation (levels were only 23.8% in 41McisR versus 41M). This was also reflected at the DNA level by a similar level of reduced DNA interstrand cross-links and total platinum-DNA adducts measured immediately after a 2-h exposure to cisplatin in 41McisR versus 41M. Conversely, for CH1cisR (resistance factor of 6.5), platinum accumulation, and initial numbers of DNA-interstrand cross-links and total DNA-platinum adducts were not significantly different from the parent CH1 line. This is suggestive of a resistance mechanism involving increased DNA repair or tolerance to platinum-DNA adducts operating in the CH1cisR/CH1 pair of lines. Cross-resistance to carboplatin and partial cross-resistance to the 1,2-diaminocyclohexane-containing agent, (trans-d,l)-1,2-diaminocyclohexane tetrachloroplatinum(IV) (tetraplatin), was observed in both pairs. However, two novel platinum(IV) ammine/amine dicarboxylates, ammine dibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) and ammine dibenzoatodichloro(propylamine)platinum(IV) (JM244), completely circumvented resistance in 41McisR to produce some collateral sensitivity (resistance factors of 0.67 and 0.54, respectively) but showed cross-resistance in CH1cisR (resistance factors of 3.7 and 4.6). In contrast to the data for cisplatin, intracellular platinum levels were not significantly different between the 41M and 41McisR pair of cell lines after exposure to JM244. These results suggest that the ammine/amine platinum(IV) dicarboxylates, which show considerably greater in vitro cytotoxicity than cisplatin, are capable of circumventing acquired cisplatin resistance which is due to decreased intracellular accumulation but are not able to overcome resistance at the level of DNA platination and removal.

¹ Supported by grants to the Institute of Cancer Research from the Cancer Research Campaign (UK), the Medical Research Council, the Johnson Matthey Technology Centre, and Bristol Myers Squibb Oncology.

² To whom requests for reprints should be addressed.

Received 1/14/92. Accepted 5/ 7/92.

This article has been cited by other articles:

				X. Wu, W. Fan, S. Xu, and Y. Zhou Sensitization to the Cytotoxicity of Cisplatin by Transfection with Nucleotide Excision Repair Gene Xeroderma Pigmentosun Group A Antisense RNA in Human Lung Adenocarcinoma Cells Clin. Cancer Res., December 1, 2003; 9(16): 5874 - 5879. [Abstract] [Full Text] [PDF]

				J. M. Perez, L. R. Kelland, E. I. Montero, F. E. Boxall, M. A. Fuertes, C. Alonso, and C. Navarro-Ranninger Antitumor and Cellular Pharmacological Properties of a Novel Platinum(IV) Complex: trans-[PtCl2(OH)2(Dimethylamine) (Isopropylamine)] Mol. Pharmacol., April 1, 2003; 63(4): 933 - 944. [Abstract] [Full Text] [PDF]

				C. Manzotti, G. Pratesi, E. Menta, R. Di Domenico, E. Cavalletti, H. H. Fiebig, L. R. Kelland, N. Farrell, D. Polizzi, R. Supino, et al. BBR 3464: A Novel Triplatinum Complex, Exhibiting a Preclinical Profile of Antitumor Efficacy Different from Cisplatin Clin. Cancer Res., July 1, 2000; 6(7): 2626 - 2634. [Abstract] [Full Text]

				D. Vandier, V. Calvez, L. Massade, A. Gouyette, L. Mickley, T. Fojo, and O. Rixe Transactivation of the Metallothionein Promoter in Cisplatin-Resistant Cancer Cells: a Specific Gene Therapy Strategy J Natl Cancer Inst, April 19, 2000; 92(8): 642 - 647. [Abstract] [Full Text] [PDF]

				B. Leyland-Jones, L. R. Kelland, K. R. Harrap, and L. R. Hiorns Genomic Imbalances Associated with Acquired Resistance to Platinum Analogues Am. J. Pathol., July 1, 1999; 155(1): 77 - 84. [Abstract] [Full Text] [PDF]